-
公开(公告)号：US11370742B2
公开(公告)日：2022-06-28
申请号：US17261731
申请日：2019-07-23
申请人： FAES FARMA, S.A.
发明人： Gonzalo Hernández Herrero , Neftalí García Domínguez , Pablo Morán Poladura , Tania González García , Álvaro Ganza González , Paloma Tato Cerdeiras
IPC分类号： C07C67/42 , C07C45/46 , C07D235/04 , C07D401/04 , C07C51/09 , C07C67/00
摘要： The invention relates to a process for preparing a compound of (III) wherein X is a leaving group; and R1 is C1-C6 alkyl; which comprises oxidative rearrangement of a compound of formula (II) or a solvate thereof Compounds of formula (III) are key intermediates in the synthesis of Bilastine.
-
公开(公告)号：US20180016251A1
公开(公告)日：2018-01-18
申请号：US15540905
申请日：2015-12-28
申请人： Faes Farma, S.A.
发明人： Rosa RODES SOLANES , Roberto OLIVERA TIZNE , Gonzalo HERNÁNDEZ HERRERO , Victor RUBIO ROYO , Francisco LEDO GÓMEZ
IPC分类号： C07D401/04 , C07D471/04 , C07D401/14
CPC分类号： C07D401/04 , C07D401/14 , C07D471/04
摘要： The invention relates to compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, a method of synthesis of said compounds, pharmaceutical compositions comprising them and their use in the treatment and/or prevention of conditions mediated by H1 histamine receptor, such as allergic disorders or diseases.
-
公开(公告)号：US20170348249A1
公开(公告)日：2017-12-07
申请号：US15524174
申请日：2016-02-05
申请人： FAES FARMA, S.A.
发明人： Josep María Suñé Negre , Ignacio Ortega Azpitarte , Pepa Del Arenal Barrios , Gonzalo Hernández Herrero
IPC分类号： A61K31/047 , A61K9/48
摘要： The present invention relates to calcifediol soft capsules, to their use in the treatment or prevention of diseases related to vitamin D deficiency, such as vitamin D deficiency, demineralization such as hypocalcemia and hypophosphatemia, renal osteodystrophy, rickets, osteoporosis, osteopenia, osteoarthritis, osteoarthrosis, osteomalacia, hypoparathyroidism, and inflammatory bowel disease, and to their process of manufacture.
-
公开(公告)号：US11591280B2
公开(公告)日：2023-02-28
申请号：US17606807
申请日：2020-05-12
申请人： FAES FARMA, S.A.
发明人： Gonzalo Hernández Herrero , Neftalí García Domínguez , Tatiana María Suárez Cortés , Tania González García , Generosa Gómez Pácios , Yagamare Fall Diop , Hugo Santalla García , Fátima Garrido Fernández
IPC分类号： C07C41/48 , C07C43/188 , C07F7/18 , C07C401/00
摘要： The invention relates to new intermediates in the synthesis of Eldecalcitol and to processes for the preparation of said intermediates and of Eldecalcitol.
-
公开(公告)号：US20220204433A1
公开(公告)日：2022-06-30
申请号：US17606807
申请日：2020-05-12
申请人： FAES FARMA, S.A.
发明人： Gonzalo HERNÁNDEZ HERRERO , Neftalí GARCÍA DOMCÍNGUEZ , Tatiana María SUÁREZ CORTÉS , Tania GONZÁLEZ GARCÍA , Generosa GÓMEZ PÁCIOS , Yagamare FALL DIOP , Hugo SANTALALLA GARCÍA , Fátima GARRIDO FERNÁNDEZ
IPC分类号： C07C43/188
摘要： The invention relates to new intermediates in the synthesis of Eldecalcitol and to processes for the preparation of said intermediates and of Eldecalcitol.
-
公开(公告)号：US20210300856A1
公开(公告)日：2021-09-30
申请号：US17261731
申请日：2019-07-23
申请人： FAES FARMA, S.A.
发明人： Gonzalo HERNÁNDEZ HERRERO , Neftalí GARCÍA DOMÍNGUEZ , Pablo MORÁN POLADURA , Tania GONZÁLEZ GARCÍA , Álvaro GANZA GONZÁLEZ , Paloma TATO CERDEIRAS
IPC分类号： C07C67/42 , C07C45/46 , C07D235/04
摘要： The invention relates to a process for preparing a compound of (III) wherein X is a leaving group; and R1 is C1-C6 alkyl; which comprises oxidative rearrangement of a compound of formula (II) or a solvate thereof Compounds of formula (III) are key intermediates in the synthesis of Bilastine.
-
公开(公告)号：US10106522B2
公开(公告)日：2018-10-23
申请号：US15540905
申请日：2015-12-28
申请人： Faes Farma, S.A.
发明人： Rosa Rodes Solanes , Roberto Olivera Tizne , Gonzalo Hernández Herrero , Víctor Rubio Royo , Francisco Ledo Gómez
IPC分类号： C07D401/04 , C07D401/14 , C07D471/04
摘要： The invention relates to compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, a method of synthesis of said compounds, pharmaceutical compositions comprising them and their use in the treatment and/or prevention of conditions mediated by H1 histamine receptor, such as allergic disorders or diseases.
-
公开(公告)号：US20230181555A1
公开(公告)日：2023-06-15
申请号：US17604263
申请日：2020-04-15
申请人： FAES FARMA, S.A.
发明人： Gonzalo HERNÁNDEZ HERRERO , Ana GONZALO GOROSTIZA , Patricia MARCIANES MORENO , Paula GONZÁLEZ FERNÁNDEZ , Paloma TATO CERDEIRAS
IPC分类号： A61K31/454 , A61K9/06 , A61K47/18 , A61K47/40 , A61K31/569 , A61K9/00
CPC分类号： A61K31/454 , A61K9/06 , A61K47/186 , A61K47/40 , A61K31/569 , A61K9/0043
摘要： The invention relates to an aqueous pharmaceutical composition comprising:
a) bilastine, or a pharmaceutically acceptable salt or solvate thereof,
b) benzalkonium chloride, in combination with at least one further preservative selected from the group comprising phenylethyl alcohol, benzyl alcohol, sodium benzoate, chlorbutanol, phenoxyethanol, cetrimide and 2-(ethylmercuriomercapto)benzoic acid sodium salt,
c) a suspending agent, and
d) 2-hydroxypropyl-β-cyclodextrin;
wherein the pH of the aqueous pharmaceutical composition is between 3.5 and 5.5.
The invention also relates to said compositions for use in the treatment and/or prevention of a disorder or disease susceptible to amelioration by antagonism of H1 histamine receptor and/or of a corticosteroid-responsive disease through nasal administration.
The invention also relates to a process for preparing the aqueous pharmaceutical composition above mentioned.-
公开(公告)号：US11642309B2
公开(公告)日：2023-05-09
申请号：US16756112
申请日：2018-10-15
申请人： FAES FARMA, S.A.
发明人： Gonzalo Hernández Herrero , Ana Gonzalo Gorostiza , Neftalí García Domínguez , Arturo Zazpe Arce , Pablo Morán Poladura , Tania González García
CPC分类号： A61K9/0043 , A61K9/10 , A61K31/454 , A61K31/58 , A61K47/38 , A61K47/40
摘要： The invention relates to an aqueous pharmaceutical composition comprising:
a) bilastine
or a pharmaceutically acceptable salt or solvate thereof,
b) mometasone, or a pharmaceutically acceptable derivative thereof,
c) a suspending agent, and
d) 2-hydroxypropyl-β-cyclodextrin;
wherein the pH of the aqueous pharmaceutical composition is between 3.5 and 5.5, and wherein the content of 2-hydroxypropyl-β-cyclodextrin is less than 8.5% by weight.
The invention also relates to said compositions for use in the treatment and/or prevention of a disorder or disease susceptible to amelioration by antagonism of H1 histamine receptor and/or of a corticosteroid-responsive disease through nasal administration.
The invention also relates to a process for preparing the aqueous pharmaceutical composition above mentioned.-
公开(公告)号：US20210186869A1
公开(公告)日：2021-06-24
申请号：US16756112
申请日：2018-10-15
申请人： FAES FARMA, S.A.
发明人： Gonzalo HERNÁNDEZ HERRERO , Ana GONZALO GOROSTIZA , Neftalí GARCÍA DOMÍNGUEZ , Arturo ZAZPE ARCE , Pablo MORÁN POLADURA , Tania GONZÁLEZ GARCÍA
摘要： The invention relates to an aqueous pharmaceutical composition comprising: a) bilastine or a pharmaceutically acceptable salt or solvate thereof, b) mometasone, or a pharmaceutically acceptable derivative thereof, c) a suspending agent, and d) 2-hydroxypropyl-β-cyclodextrin; wherein the pH of the aqueous pharmaceutical composition is between 3.5 and 5.5, and wherein the content of 2-hydroxypropyl-β-cyclodextrin is less than 8.5% by weight. The invention also relates to said compositions for use in the treatment and/or prevention of a disorder or disease susceptible to amelioration by antagonism of H1 histamine receptor and/or of a corticosteroid-responsive disease through nasal administration.
The invention also relates to a process for preparing the aqueous pharmaceutical composition above mentioned.
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.014 秒)
